Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL28516249 | 1.00 | — | — | |
| Acetonitrile SCHEMBL6487601 | 1.00 | APLNR (0.33) | APLNR | |
| Acetonitrile SCHEMBL16267560 | 1.00 | APLNR (0.33) | APLNR | |
| Acetonitrile SCHEMBL522737 | 1.00 | — | — | |
| Acetonitrile SCHEMBL9936942 | 1.00 | APLNR (0.33) | APLNR | |
| Acetonitrile SCHEMBL4448760 | 1.00 | APLNR (0.33) | APLNR | |
| Acetonitrile SCHEMBL15092908 | 1.00 | APLNR (0.33) | APLNR | |
| Acetonitrile SCHEMBL16267901 | 1.00 | APLNR (0.33) | APLNR | |
| Acetonitrile SCHEMBL15092655 | 1.00 | APLNR (0.33) | APLNR | |
| Acetonitrile SCHEMBL89046 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2020-08-04 | — | — | US | disclosed |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2019-04-11 | — | — | US | disclosed |
| US-9872864-B2 | Sustained release composition of prostacyclin | ASCENDIS PHARMA A/S (DK) | 2018-01-23 | — | — | US | disclosed |
| US-9561287-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2017-02-07 | — | — | US | disclosed |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | ASCENDIS PHARMA A/S (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| EP-2741738-A1 | SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741781-A1 | CARRIER-LINKED TREPROSTINIL PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| CN-103874480-A | Sustained release composition of prostacyclin | ASCENDIS PHARMA AS | 2014-06-18 | — | — | CN | disclosed |
| WO-2013024051-A1 | SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024052-A1 | CARRIER-LINKED TREPROSTINIL PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | APLNR 2507/4885 |
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | PAH, SLC16A1, SLC34A3 | APLNR 2424/4885 |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | PTGIR, PTGIS, PTGS1 | APLNR 971/4885 |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | APLNR 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.